Sembiosys Genetics Inc is a biotechnology firm founded in 1994, specializing in plant biotechnology. The company is focused on producing high-value pharmaceutical and non-pharmaceutical products in a cost-effective and sustainable manner. Their innovative plant technology enables the affordable production of drugs needed in large quantities to address the healthcare needs of a significant population. Their current focus includes solutions targeting diabetes (insulin) and cardiovascular disease (Apo AIMilano), as well as nutritional supplements and agricultural biotechnology products. Notably, their associate company, Botaneco, is leveraging the same technology to develop skincare products. The latest funding, a Venture Round investment, took place on 01 October 2020 and was led by Bay City Capital. Sembiosys Genetics Inc aims to play a pivotal role in providing affordable healthcare solutions by becoming a leader in the development of sustainable pharmaceutical and non-pharmaceutical products.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
01 Oct 2020 |
| Venture Round | $4.00M | 1 | Concept Capital | 18 Mar 2011 |
| Venture Round | $1.50M | 1 | Verdex Capital (Formerly the AVAC Group ) | 31 Jan 2002 |
No recent news or press coverage available for Sembiosys Genetics Inc.
We care about your data, and we'd love to use cookies make your experience better.